use of violacein, in free or encapsulated form in polymeric systems as antimalarial. field of the invention the present invention relates to the use of violacein extracted from chromobacterium violaceum and its formulations, in nano- and micro-particulate biodegradable polymeric systems, for the manufacture of medicines for application in the area of human health directly in the treatment of malarial infections already established. the antimalarial activity discovered was found, in vivo, in an experimental infection model using isogenic mice infected with blood forms of plasmodium chabaudi and, in vitro, against blood stages of plasmodium falciparum, the main cause of malaria in humans. fundamentals of the invention malaria remains the main parasitic disease in the world, causing morbidity and mortality in tropical and subtropical regions in more than 100 countries. it is estimated that this disease puts at risk 2.4 billion people, mainly those exposed to infection by plasmodium falciparum and p. vivax, responsible for about 100-300 and 70-80 million of annual cases respectively (who, who wkly. epidem. rec. 22, 161 (1997)； mendis et al., am. j. trop. med. hyg 64, 97 (2001)). in Brazil, about 500,000 cases of malaria were registered, mainly in the Amazon region, 76.4% of which were registereduso da violaceína, na forma livre ou encapsulada em sistemas poliméricos como antimalárico. campo da invenção a presente invenção se refere ao uso da violaceína extraída da chromobacterium violaceum e de suas formulações,em sistemas poliméricos biodegradáveis nano- e micro-particulados, para manufatura de medicamentos para aplicação na área da saúde humana diretamente no tratamento de infecções maláricas já estabelecidas. a atividade antimalárica descoberta foi constatada, in vivo, em modelo de infecção experimental utilizando camundongos isogênicos infectados com formas sangüíneas de plasmodium chabaudi e, in vitro, contra estágios sangüíneos de plasmodium falciparum, principal
